---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-26-000062"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2026-05-20T11:14:07+00:00"
generated_at: "2026-05-20T11:16:02.795515+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunovant posts $0.73/sh Q4 loss; IMVT-1402 hits 72.7% ACR20 in D2T RA at Week 16

## Summary
- IMVT-1402 in D2T RA: 72.7% ACR20, 54.5% ACR50, 35.8% ACR70 at Week 16; open-label, blinded assessors; safety well-tolerated.
- Cash $902.1M as of Mar 31, 2026; provides runway to potential launch of IMVT-1402 in GD.
- Net loss Q4 FY2026 $147.9M ($0.73/share) vs $106.4M ($0.64/share) YoY; FY net loss $505.6M ($2.77/share).
- Batoclimab discontinued after Phase 3 TED miss; $39M contract cost recognized in Q4.
- CLE proof-of-concept fully enrolled; topline data expected H2 2026. Other trials on track for GD, MG, CIDP, SjD.

## SEC filing metadata
- accession: 0001764013-26-000062
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2026-05-20T11:14:07+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/0001764013-26-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/imvt-20260520.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-26-000062
- JSON: https://secwatch.observer/filing/0001764013-26-000062.json
- Plain text: https://secwatch.observer/filing/0001764013-26-000062.txt

## Key facts
- Earnings Releases
  Immunovant, Inc. reported fourth quarter and fiscal year ended March 31, 2026 results: net income $147.9 million ($0.73 per common share), EPS ($0.73 per common share).
  - Period: fourth quarter and fiscal year ended March 31, 2026
  - Net income: $147.9 million ($0.73 per common share)
  - EPS: ($0.73 per common share)
  - Result: reported results
  source text: Net loss was $147.9 million ($0.73 per common share) for the three months ended March 31, 2026, compared to $106.4 million ($0.64 per common share) for the three months ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/0001764013-26-000062-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.